WO2010104309A2 - Compositions for preventing or improving gastrointestinal diseases - Google Patents

Abstract

The present invention provides compositions containing two or more herbal medicines selected from a group consisting of Bupleuri Radix, Coptidis Rhizoma, and Glycyrrhizae Radix for preventing or treating gastrointestinal diseases, and provides medicines and functional health foods containing the compositions. The compositions according to the present invention contain a combination of two or more of Bupleuri Radix, Coptidis Rhizoma, and Glycyrrhizae Radix, to exhibit remarkable effects, which are unforeseeable by those skilled in the art, in treating gastrointestinal diseases related to mucosal injury caused by a stomach ulcer or a duodenal ulcer. The compositions according to the present invention are desirable as they are made of natural materials so as to not impart any toxicity to the human body and result in little risk of the diseases recurring. Consequently, the compositions according to the present invention can be used as medicines or functional health foods for preventing or treating a variety of gastrointestinal diseases caused by alcohol, stress, smoking, drugs, or the like.

Description

Composition for preventing or improving gastrointestinal diseases

The present invention relates to a composition for the prevention or treatment of gastrointestinal diseases, and more particularly, to a composition for the prevention or treatment of gastrointestinal diseases, the effect of which is significantly improved by including a combination of herbal ingredients known to be effective in the treatment of conventional gastrointestinal diseases. will be.

The stomach secretes gastric acid, a strong acid, to digest foods, where the protective layer of mucosa acts to prevent damage to the gastric mucosa by gastric acid. Inflammation with erosion, redness, bleeding, and edema occurs when gastric acid secretion is increased or gastric mucosal protective layer is damaged by various factors, and this inflammatory lesion is limited to the gastric mucosa. It is called gastric ulcer when it is severely damaged and penetrates the gastric mucosa and damages the submucosal tissue and muscle layer. In addition, the duodenum, which is directly connected to the stomach, may cause inflammation and duodenal ulcer by similar factors, and gastric ulcer and duodenal ulcer are collectively referred to as peptic ulcer.

The causes of gastritis and gastric ulcers can be broadly divided into pathological excesses of attack factors such as excessive gastric acid secretion and weakening of protective factors that protect gastric mucosal cells from gastric acid attack. Gastric ulcer drugs have been developed and used as inhibitors and enhancers of defense factors. Representative attack factors include gastric acid, pepsin, alcohol and smoking, stress and nonsteroidal anti-inflammatory drugs, infections of Helicobacter pylori ( Helicobacter pylori ). Factors that weaken the defensive factors include loss of structure and form of the gastric mucosa, decreased mucus secretion, decreased bicarbonate secretion, and decreased prostaglandin production.

In order to treat inflammation and ulcer of stomach and duodenum caused by attack factors, gastric acid secretion, mucous secretion promotion, gastric mucosal epithelial cell regeneration, inhibition of Helicobacter pylori proliferation and administration of anti-inflammatory drugs are required. The most representative agents for the treatment of gastritis and gastric ulcers are drugs such as antacid, H2-receptor antagonist (H2-RA), proton pump inhibitor (PPI) and gastric mucosa protector for acid secretion. A combination of these drugs and antibiotics is being used to eliminate Helicobacter pylori. However, these gastric acid secretion inhibitors have a high recurrence rate after the end of the drug administration [Drug Intell. Clin. Pharm., 21: 493, 1987; Gut, 30: 449, 1989; Yale J. Biol. Med., 65: 649, 1992]. In the case of long-term administration, some side effects have been reported, such as drug accumulation in the body and the drug persists even if the drug is stopped, or the stomach wall is thickened by the drug. Therefore, if only H2 inhibitor and proton pump inhibitor are used for gastric acid secretion, the recurrence of the most problematic lesion in the treatment of peptic ulcer cannot be suppressed, and long term administration is impossible if the disease progresses to chronic disease.

Gastric mucosal protection agents are known to regenerate mucosal tissue to a similar level as normal to compensate for the shortcomings of these fast-acting gastric acid secretion inhibitors (Folia Pharmacol. Japan, 92: 389, 1988) and are an important part of the treatment of gastritis. . However, gastric mucosa protective agents have the disadvantage that they are fast-acting, high-dose, and have to be taken for a relatively long time.

Although the treatment for peptic ulcer has been developed into various classes of drugs and various treatment strategies using the respective drugs can be suggested, they do not fundamentally show a direct healing effect to heal wounds of peptic ulcer. These drugs only play a role in suppressing the attack from gastric acid to keep the wounds from worsening, and the disappearance of the ulcer is inevitably dependent on the body's natural healing power. This limitation means that long-term drug administration is required for the treatment of peptic ulcer and that the short-term acute toxicity of the drug as well as chronic toxicity and its side effects can be considered as a good treatment.

Therefore, there is an urgent need to develop a therapeutic agent that can shorten the healing period and reduce the recurrence rate of peptic ulcer, and as an alternative, the possibility of developing various herbal extracts as a gastritis treatment agent has been reported.

Korean Patent Laid-Open Publication No. 1996-0021054 discloses a composition for treating gastrointestinal diseases comprising mugwort leaf extract as an active ingredient, and the composition for treating gastrointestinal diseases is commercialized as styrene tablets and sold and prescribed as a successful natural gastritis treatment.

Buleuri Radix is the root of the perennial herbaceous Bupleurum falcatum and the cohort of related plants (9 Korean Revisions, 2007), which are rooted in spring and autumn to remove seedlings and mud and dried in the sun. Use it. Shiho's main pharmacological actions include anti-inflammatory, antipyretic, diuretic, anti-ulcer, sedative and antifungal actions, and anti-pathogenic effects.

Coptis Rhizoma is a rhizome ( Coptis japonica ), a perennial herbaceous plant of the Ranunculuaceae, and a root stem that almost eliminates the roots of the same plant (9 KP, 2007). Dry it in the sun and remove the cork layer. The main pharmacological action of Huangshan is known as anti-inflammatory, anti-ulcer, anti-cancer, anti-radiation, anti-microbial and anti-pathogenic action.

Licorice (Glycyrrhizae Radix) is the same as or without the roots and cuticles of perennial herbaceous ( Glycyrrhiza uralensis ) and Glycyrrhiza glabra or other similar plants. 2007], roots are cut in autumn to remove stems, twigs and beard roots, cut to length and sun-dried. The main pharmacological actions of licorice are known as a wide range of detoxification, antidiuresis, antitussive expectoration, anti-inflammatory, anti-allergic, anti-ulcer, and interpolation.

Although each of the shiho, rhubarb, and licorice are known to have anti-ulcer activity, they do not have sufficient effects to be used as a medicament for preventing or treating gastrointestinal diseases, and a composition for preventing or treating gastrointestinal diseases having better effects. Development is needed.

Accordingly, the present inventors recognized the necessity of developing a composition for the prevention or treatment of gastrointestinal diseases caused by mucosal damage of the stomach or duodenum, and studied the composition for the prevention or treatment of gastrointestinal diseases with superior effects. The present invention has been found to have a significant gastrointestinal disease prevention and treatment effect when compared to the case of including a combination of two or more of, and licorice, each of which alone is unpredictable.

Accordingly, it is an object of the present invention to provide a composition for the prevention or treatment of effective gastrointestinal diseases comprising a combination of herbal medicines as an active ingredient.

Another object of the present invention to provide a pharmaceutical and health functional food comprising the composition for the prevention or treatment of gastrointestinal diseases.

In order to achieve the above object, the present invention

Provided are compositions for the prevention or treatment of gastrointestinal diseases, including two or more herbal drugs selected from the group consisting of Bupleuri Radix, Coptidis Rhizoma, and Glycyrrhizae Radix.

The present invention also provides a medicament comprising the composition and a pharmaceutically acceptable carrier or additive.

The present invention also provides a dietary supplement comprising the composition and a food acceptable carrier or additive.

Hereinafter, the present invention will be described in more detail.

The composition for the prevention or treatment of gastrointestinal diseases according to the present invention is unpredictable to those skilled in the art in the prevention or treatment effect of gastrointestinal diseases as a result of combining two or more of Siho, rhubarb, and licorice, which are known to have an anti-ulcer effect. It turned out that there was remarkable effect of degree and was completed.

Accordingly, in one aspect, the present invention provides a composition for preventing or treating gastrointestinal diseases, including two or more herbal drugs selected from the group consisting of Buleuri Radix, Cooptidis Rhizoma, and Licorice (Glycyrrhizae Radix). .

Shiho, rhubarb, and licorice in the composition is not particularly limited in the combination ratio thereof, but may preferably comprise a ratio of 10-30 parts by weight of sulfur and 10-30 parts by weight of licorice with respect to 100 parts by weight of shiho. .

The herbal medicines constituting the composition of the present invention are obviously equivalent to those in the art, and include all the herbal medicines that can be used for the prevention or treatment of gastrointestinal diseases.

The shiho, rhubarb, and licorice each may be contained in the composition as a solvent extract of the herbal medicine, and may be contained in a pulverized product of the herbal medicine, a pulverized product of the dried herbal medicine, and the like. . Solvent extract of the crude drug can be extracted by each of the herbal separately or together water, an organic solvent, or a combination thereof, as the organic solvent is C ₁ -C ₄ alcohol, acetone, chloroform, methylene chloride, ether, Ethyl acetate, hexane, or a combination thereof may be used, but is not limited thereto. Examples of C ₁ -C ₄ alcohols include methanol, ethanol, propanol and butanol, and ethanol is most preferred.

The solvent extracts of shiho, rhubarb, and licorice may be prepared by any extraction method known to those skilled in the art of herbal extraction, but 10 to 80 at an extraction temperature of 10 ° C. to 80 ° C., preferably room temperature (25 ° C.). Using extraction methods such as hot water extraction, cold sediment extraction, reflux cooling extraction or ultrasonic extraction for 2 hours to 3 days, preferably, extraction may be carried out one to five times in succession by cold extraction. . The solvent extract thus obtained can be obtained as a final extract by filtration under reduced pressure and the filtration extract is concentrated under reduced pressure at 20 to 100 ° C., preferably at room temperature (25 ° C.) with a rotary evaporator and lyophilized.

The composition comprising a combination of two or more of Siho, rhubarb, and licorice according to the present invention is effective in preventing or treating gastrointestinal diseases, and the gastrointestinal diseases include all gastrointestinal diseases known to be caused by mucosal damage of the stomach and twelve limbs. . The gastrointestinal disease may be caused by various causes such as alcohol, smoking, stress, drugs, or a combination thereof, but is not limited thereto. Drugs that cause the gastrointestinal disorders include, but are not limited to, nonsteroidal anti-inflammatory agents, steroids, and the like. The nonsteroidal anti-inflammatory agents are typically indomethacin, diclofenac, aspirin, acetaminophen, ibuprofen, meloxycamp, naproxen and the like.

The prophylactic or therapeutic effect of such gastrointestinal diseases of the compositions according to the invention was demonstrated in the following examples. Specifically, as a result of administering to a rat a composition comprising a composition comprising a combination of two or more of sea lakes, yellow lotus, and licorice according to the present invention and causing gastric ulceration by alcohol, water restraint, or nonsteroidal anti-inflammatory drugs (NSAIDs), Compared to the non-administered group (control group) of the composition according to the present invention, the ulcer index was significantly lower in the administration group, and it was confirmed to show a remarkably superior effect compared to styrene tablets widely used as a conventional herbal medicine for treating gastrointestinal diseases. The preventive effect of In addition, after inducing direct ulceration of gastric tissue by acetic acid, a long term administration of a composition comprising a combination of two or more of sea tiger, yellow lotus, and licorice according to the present invention is followed by anti-ulcer action and mucosal regeneration effect by prostaglandins. As a result, the gastrointestinal disease treatment index was remarkably excellent in the administration group compared to the non-administration group (control group) of the composition according to the present invention, and showed a remarkably superior effect compared to the styrene tablet widely used as a conventional herbal medicine for treating gastrointestinal diseases It has been confirmed that the therapeutic effect of gastrointestinal diseases has been proved. In addition, as a result of comparing the composition comprising two or more combinations of Shiho, Huang lotus, and licorice according to the present invention with a composition comprising each of Shiho, Huang lotus, or licorice alone, the respective doses are the same. In the case of the composition comprising two or more herbal medicines according to the present invention when administered as compared to the case of administering each herbal extract alone, the effect of inhibiting gastric damage in rats is higher, thus preventing and treating gastrointestinal diseases. It has been proven to have synergistic action. Among the compositions according to the present invention, in particular, the case comprising all three lakes, yellow lotuses, and licorice has not only a synergistic effect, but also a composition containing two wild herbs, respectively. It was confirmed to have a synergistic effect compared with that. Furthermore, the composition according to the present invention contains herbal medicines that have been proven to be safe while being used for a very long time, and thus have little toxicity and side effects, and thus can be used safely for long-term treatment or for long-term treatment of gastrointestinal diseases.

Thus, in another aspect, the present invention provides a medicament comprising the composition according to the present invention, and a pharmaceutically acceptable carrier or additive.

The drug may be administered to various mammals including rats, mice, livestock, humans, etc. by various routes, for example oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injections. May be administered. Accordingly, the medicament may be formulated in conventional pharmaceutical formulations known in the art. The medicament may be formulated and administered in any dosage form including, but not limited to, oral, injectable, suppository, transdermal, and non-administrative agents, but preferably liquids, suspensions, powders, granules, It may be formulated in oral dosage forms such as tablets, capsules, pills, emulsions, syrups, aerosols, or extracts.

When formulated into each of the above formulations, it may be prepared by the addition of a pharmaceutically acceptable carrier or additive necessary for the preparation of each formulation. Representatively, when formulated into a dosage form for oral administration, one or more of a diluent, a lubricant, a binder, a disintegrant, a sweetener, a stabilizer, and a preservative may be used as the carrier, and as an additive, flavors, vitamins, and antioxidants may be used. One or more types can be selected and used out of them.

The carrier and the additive may be any pharmaceutically acceptable, specifically, as a diluent, lactose, dextrose, sucrose, corn starch, soybean oil, microcrystalline cellulose, sorbitol, xylitol, or mannitol, magnesium stearate as a lubricant, As talc and a binder, polyvinylpyrrolidone or hydroxypropyl cellulose is preferable. In addition, as a disintegrant, calcium carboxymethyl cellulose, sodium starch glycolate, potassium polyacrylic acid, or crospovidone, sweetener as white sugar, fructose, sorbitol, or aspartame, stabilizer as carboxymethyl cellulose sodium, beta-cyclodextrin, As lead, or xanthan gum, and preservative, methyl paraoxybenzoate, propyl paraoxybenzoate, or potassium sorbate is preferable.

In addition to the above ingredients, in order to enhance the taste as well-known additives, natural flavors such as plum, lemon, pineapple, herb, natural pigments, such as fruit juice, chlorophyllin, flavonoids, fructose, honey, sugar alcohol, sugar Sweetening ingredients such as, or may be used by mixing an acidulant such as citric acid, sodium citrate.

Among the preparations for parenteral administration, there are sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. For the preparation of non-aqueous solvents and suspending agents, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. As a base of suppositories, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol gelatin and the like can be used.

The drug can be appropriately added to or lowered the mixing ratio of the constituent herb appropriately within the range that effectively maintains the therapeutic or prophylactic effect of gastrointestinal diseases, 0.01-80% by weight of the herbal component constituting the composition according to the present invention, Preferably 1-50% by weight.

In order to obtain a prophylactic or therapeutic effect of gastrointestinal disorders, the pharmaceutical product may contain 0.01-10 g / kg / day, preferably 1-5 g / kg / day, based on the dry powder of the solvent extract. It may be administered once or several times a day, and may be appropriately increased or decreased depending on the age, sex, weight, diet, excretion rate, and other drugs currently being taken. Therefore, the pharmaceutical preparation according to the present invention is to be prepared in consideration of the range of effective amount, and the dosage unit formulation formulated in this way is a specialized dosage according to the judgment of experts and the needs of the individual to monitor or observe the administration of the drug as necessary It may be administered several times at intervals using a method or at regular intervals.

The composition according to the present invention can also be used as a raw material of health functional food for the prevention or treatment of gastrointestinal diseases.

Thus, in another aspect, the present invention provides a dietary supplement comprising the composition according to the present invention, and a food acceptable carrier or additive.

Health functional foods defined in the present invention is a health function prescribed in the Food and Drug Administration Notice 2008-72 is sufficiently established that the newly defined functional and safety for the human body through the Act on Health Functional Foods amended in 2008 It means that it is a health functional food as listed in the regulations on the recognition of food functional ingredients.

Such dietary supplements can be formulated in the formulation of conventional dietary supplements known in the art. The dietary supplement may be prepared, for example, as a powder, granules, tablets, pills, capsules, suspensions, emulsions, syrups, dips, liquids, extracts, gums, teas, jelly, or beverages. As the food acceptable carrier or additive, any carrier or additive known to be usable in the art may be used to prepare a formulation to be prepared.

The dietary supplement may comprise 0.01 to 15% by weight, preferably 0.2 to 10% by weight of the total weight of the food ingredients constituting the composition according to the present invention, based on 100 mL when prepared as a beverage In the range of 0.1 to 30 g, preferably 0.2 to 5 g.

The beverage may further contain other ingredients in addition to the herbal ingredients, and may further contain various flavors or natural carbohydrates, etc. that are commonly used in beverages. The natural carbohydrates include conventional sugars such as monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), polysaccharides (e.g., dextrin, cyclodextrin, etc.) and xylitol, sorbitol, erythritol, etc. Sugar alcohols may be contained. In addition, the flavoring agent may contain natural flavoring agents (e.g., taumartin, stevia extract, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.). The proportion of the natural carbohydrate is preferably contained in about 1 to 20 g, preferably about 5 to 12 g per 100 mL of beverage.

The drug and the health supplement according to the present invention may be administered simultaneously with two or more combinations of Shiho, rhubarb, and licorice, which are included as active ingredients, but the extent to which the composition can prevent or treat gastrointestinal diseases It may be administered sequentially at predetermined intervals within. If two or more combinations of shiho, rhubarb and licorice are to be administered at predetermined intervals, each active ingredient may be formulated in a separate, separate formulation. When two or more combinations of shiho, rhubarb, and licorice are to be administered simultaneously, they may be formulated in a uniformly mixed form in one formulation, or may be formulated in separate formulations and then administered simultaneously.

 As described above, the composition according to the present invention comprises a combination of two or more of shiho, yellow lotus, and licorice, thereby having a remarkably effective effect in the treatment of gastrointestinal diseases associated with mucosal damage of the gastrointestinal or duodenal ulcer. It is preferable because it is composed of natural materials, so it has little toxicity to human body and little risk of recurrence. Therefore, the composition according to the present invention can be used as a medicine or health functional food for the prevention or treatment of various gastrointestinal diseases caused by alcohol, stress, smoking, or drugs.

1 and 2 are photographs of the herbal extract prepared according to one embodiment of the present invention to observe the inhibitory effect of gastric damage caused by diclofenac.

Figure 3 is a photograph of the herbal extract prepared according to an embodiment of the present invention to observe the effect of preventing gastric damage caused by indomethacin intraperitoneal administration through tissue staining.

Figure 4 is a photograph of the herbal extract prepared according to an embodiment of the present invention observed the effect of treating subacute gastric injury induced by acetic acid through tissue staining.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are only for the understanding of the present invention, and the scope of the present invention is not limited by them in any sense.

Comparative Example 1-3: Preparation of Single Herb Extracts of Sea Tiger, Yellow Lotus, and Licorice

Shiho, rhubarb and licorice dried on Chinese herbal medicine were purchased, washed with water to remove contaminants, and a well-dried herbal medicine was used for the preparation of the extract. 200 g of Siho, rhubarb and licorice in the well pulverized state were each taken, and 400 mL of 80% ethanol aqueous solution was added to each of them, followed by chilling for 3 days at room temperature to obtain respective liquid extracts. The respective liquid extracts were filtered, concentrated under reduced pressure at 50 ° C. with a rotary evaporator, completely removed by drying with a solvent in a vacuum oven, and then powdered. Finally, 31 g of Siho extract (Comparative Example 1) and yellow lotus were obtained. Ethanol dry extract of 36 g of extract (Comparative Example 2) and 48 g of Licorice extract (Comparative Example 3) was obtained.

Example 1-3 Preparation of Extracts of Two Combinations of Seahawks, Rhubarb and Licorice

Shiho, rhubarb and licorice dried on Chinese herbal medicine were purchased, washed with water to remove contaminants, and a well-dried herbal medicine was used for the preparation of the extract. 780g and 180g (Example 1) of sea tiger and rhubarb, respectively, finely ground with a grinder, 780g and 180g (Example 2) of sea tiger and licorice, respectively, and 500g of rhubarb and licorice, respectively (Example 3) 2L each of 80% ethanol aqueous solution was added to each combination of herbal medicines, followed by extraction, filtration, concentration and drying in the same manner as in Comparative Example 1-3, and each ethanol dry extract Shiho-Russian extract 165g (Example 1), Shiho- 192 g of licorice extract (Example 2) and 210 g of Hulk-Licorice extract (Example 3) were obtained.

Example 4 Preparation of a Mixed Extract of Seahawks, Rhubarb and Licorice

Shiho, rhubarb and licorice dried on Chinese herbal medicine were purchased, washed with water to remove contaminants, and a well-dried herbal medicine was used for the preparation of the extract.

Siho and rhubarb in well-pulverized state, 6.5 kg, rhubarb 1.5 kg, and licorice 1.5 kg were added to the extractor, and 20 L of 80% ethanol aqueous solution was added thereto, followed by extraction, filtration, concentration, and the like. Finally, 1.6 kg of ethanol dry extract was obtained from Shiho-Ranso-Licorice extract.

Experimental Example 1: Test of the inhibitory effect of alcohol-induced gastric injury (1)

Rat model experiment using 60% ethanol prepared with 150 mM HCl solution as a gastric injury inducing factor was performed to evaluate the gastric mucosal protection effect of the herbal extract prepared in Example 1-4. Ethanol causes bleeding and swelling of the submucosal muscle layer by direct stimulation of the gastric mucosa, causing temporary ischemia, causing necrosis of cells, reducing the amount of ATP in the mucosa and congestion of microcirculation. Hydrochloric acid stimulates gastrointestinal motility, causing acute gastritis.

Seven week-old male Sprague-Dawley rats with no specific pathogen (SPF) were purchased from the Charles River, followed by a week-long purifying period, and healthy rats weighing 270-280 g were used for the experiment. Each group was divided into 5 animals, and each animal was orally administered at a dose of 100 mg / kg or 200 mg / kg to the fasted animal for 20 hours under free water intake and 150 mM after 1 hour. 60% ethanol prepared with HCl solution was orally administered 1 mL per horse and gastric injury was induced for 1 hour. After 1 hour of drug administration, the rats were sacrificed by suffocation with CO ₂ , the stomach was extracted, fixed with 1% formalin solution, incised and spread along the Taiwanese area, and then the gastrointestinal damage was visually observed, the length of the gastric ulcer index was measured. Calculated.

First, a composite extract comprising each of the extracts of shiho, rhubarb and licorice prepared in Comparative Examples 1-3 and two herbal extracts of Example 1-3, and both shiho, rhubarb and licorice of Example 4 was prepared. The test groups were compared for drug efficacy against alcoholic acute gastritis. Water was administered as a control and the experimental results are shown in Table 1 below.

 [Table 1] Visual observation of gastric mucosa

According to the results shown in Table 1, the administration of two or more complex extracts of shiho, rhubarb, and licorice as in Example 1-3 is significantly superior to the case of administration of a single extract of shiho, rhubarb and licorice respectively. It was found to have an anti-ulcer effect. In addition, the case of administering the composite extracts of Shiho, Huang lotus, and licorice, as in Example 4, as well as the case of administering a single extract of Shiho, Huang lotus and licorice, as well as two or more complex extracts It was found to have a remarkably good anti-ulcer effect.

Therefore, it can be seen that the two or more herbal extracts of shiho, rhubarb, and licorice according to the present invention have a significant preventive effect against gastrointestinal diseases.

Experimental Example 2: Test of the inhibitory effect of alcohol-induced gastric injury (2)

Based on the results of Experimental Example 1, in order to confirm the efficacy of the herbal extracts prepared in Example 4, the test group was administered to the rats, the herbal extracts prepared in Example 4, styrene tablets (Comparative Example 4) Petal leaf extract 60mg, Dong-A Pharm.) Was administered to rats, and water was administered as a control to compare the efficacy. Experimental method was carried out in the same manner as in Experiment 1. The experimental results are shown in Table 2 below.

[Table 2] Visual observation of gastric mucosa

According to the results shown in Table 2, it can be seen that the herbal extract of Example 4 has a significantly better prevention of gastrointestinal diseases than styrene currently used for the treatment of gastrointestinal disorders against the gastric mucosa damaged by ethanol.

Experimental Example 3: Inhibition effect test of immersion restraint-induced stress gastric injury

In order to confirm the inhibitory effect of stress gastric injury, drug efficacy test was conducted by the submerged restraint model. When the vagus nerve is excited by stress, gastric mucosal damage is caused by gastric acid secretion, gastric motor hyperactivity, and blood flow disorder.

Seven week-old male Sprague-Dawley rats with no specific pathogens (SPF) were purchased from the Charles River, followed by a week-long purifying period, and healthy rats weighing 270-280 g were used for the experiment. Each group was divided into 5 animals, and the animals were orally administered to the fasted experimental animals for 20 hours under free water consumption, and 30 minutes later, they were placed in a stress cage so that the scalp was submerged. after put into the expanded and maintain the water temperature to 21 ± 1 ℃ and fixed with 1% formalin solution was extracted up after allowed to stand for 8 hours by following, asphyxiation with CO ₂ sacrifice the rats and cut along the Taiwan, up to the naked eye The damage was observed and the length of the gastric ulcer was measured and recorded by evaluating the gastric ulcer index.

As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare the drug efficacy. The experimental results are shown in Table 3 below.

[Table 3] Visual observation of gastric mucosa

According to the results shown in Table 3, the herbal extract of Example 4 has a significantly better prevention or treatment efficacy of gastrointestinal diseases, compared to the styrene tablets currently used for the treatment of gastrointestinal diseases, on gastric mucosa damaged by immersion restraint. It can be seen that.

Experimental Example 3 Nonsteroidal Anti-inflammatory Agents (NSAIDs) -Inhibitory Effect Test of Induced Gastric Injury (1)

Nonsteroidal anti-inflammatory agents inhibit the biosynthesis of prostaglandin (PG), leading to damage of the gastric mucosa. In order to confirm the prophylactic and inhibitory effects of gastric injury caused by these nonsteroidal anti-inflammatory drugs, the preventive effect of gastric injury by diclofenac administration was confirmed.

Seven week-old male Sprague-Dawley rats with no specific pathogens (SPF) were purchased from the Charles River, followed by a week-long purifying period, and healthy rats weighing 270-280 g were used for the experiment. Each group was divided into five so that the efficacy test was carried out under the condition that water can be freely ingested.

To confirm the inhibitory effect of acute gastric injury caused by nonsteroidal anti-inflammatory drugs, oral administration of the drug to fasted experimental animals for 20 hours, and 1 hour after oral administration of diclofenac at 50 mg / kg, left for 6 hours to cause gastric injury It was. After suffocating with CO ₂ , the rats were sacrificed and their stomachs were extracted, fixed with 1% formalin solution, incised and extended along the Taiwanese area, and the gastric ulcers were visually observed and the length of the gastric ulcer was measured and evaluated by the gastric ulcer index. In addition, photographs taken of the results of observing the damage is as shown in Figs.

As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare drug efficacy. The experimental results are shown in Table 4 below.

[Table 4] Visual observation of gastric mucosa

According to the results shown in Table 4, it can be seen that the herbal extract of Example 4 has a remarkably superior therapeutic effect against acute gastric mucosal damage caused by diclofenac compared to styrene tablets currently used as a gastrointestinal disease treatment. In addition, it can be seen from the photographs of FIGS. 1 and 2 that the gastric wall damaged by diclofenac was inhibited by administering the herbal extract of Example 4 and Comparative Example 4 (styrene tablets), and the herbal extract of Example 4 was It has been confirmed that there is a concentration-dependent gastric damage inhibitory effect.

Experimental Example 4: Non-steroidal anti-inflammatory drugs (NSAIDs)-Inhibitory effect test of induced gastric injury (2)

In order to confirm the prevention and suppression effect of gastric injury by another nonsteroidal anti-inflammatory agent, the preventive effect of gastric injury by indomethacin (indomethacin) was confirmed.

The drug was orally administered once daily for 6 days, followed by fasting for 24 hours, followed by intraperitoneal administration of indomethacin at a concentration of 70 mg / kg, and gastric injury for 7 hours. After suffocation with CO ₂ , the rats were sacrificed and the stomach was extracted, fixed with 1% formalin solution, incised and extended along the Taiwanese area, and then the gastric ulcer was visually observed and the length of the gastric ulcer was measured and evaluated by the gastric ulcer index. Blood of test animals was collected and analyzed for the content of nitric oxide (NO), superoxide dismutase (SOD) and epidermal growth factor (EGF).

As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare drug efficacy. The experimental results are shown in Table 5 below.

In addition, paraffin sections were prepared by fixing the tissue, stained, observed under a microscope, and photographed. The photograph is shown in FIG. 3.

[Table 5] Prevention of Indomethacin-induced Acute Gastric Injury

According to the results of Table 5, the herbal extract of Example 4 has a significantly superior preventive effect compared to the styrene tablets currently used as a gastrointestinal disorder treatment against gastric mucosal damage caused by intraperitoneal indomethacin administration. have.

In addition, from the photo of Figure 3, compared with the normal group (A), the gastric wall (B) damaged by indomethacin administration by administering the herbal extracts (E, F) of Comparative Example 1 (C, D) and Example 4 It was confirmed that gastric damage was prevented, and the herbal extract of Example 4 was confirmed to have a concentration-dependent inhibitory effect on gastric damage.

Experimental Example 5: Treatment effect of acetic acid-induced subchronic gastritis

After acetic acid induces direct ulceration of gastric tissue, long-term administration of anti-ulcer and prostaglandin-induced mucosal regeneration can be measured, and this model is high after 4-5 months after gross ulcer lesion loss. This model is very similar to the chronic gastric ulcer in which the ulcer recurrence is frequently observed, and it is also a useful model to confirm the therapeutic effect of chronic ulcer gastric ulcer.

Seven week-old male Sprague-Dawley rats with no specific pathogen (SPF) were purchased from the Charles River, followed by a week-long purifying period, and healthy rats weighing 270-280 g were used for the experiment. Subdivided into 5 groups for each group, anesthetized with ether under an unfastened stomach, open the stomach, and exposed to the stomach, using a microliter syringe. Inject and suture the abdomen with cotton yarn. Induce ulcers for 3 days, then orally administer the drug once a day for 14 days, fast for 24 hours after the final dose, suffocate with CO ₂ , sacrifice the rats, extract the stomach and fix with 1% formalin solution After incision and unfolding, gross damage was observed visually, the length of the gastric ulcer was measured and evaluated by the gastric ulcer index and recorded. Blood of each test animal was collected and analyzed for the content of NO, SOD and EGF in the blood.

As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare the drug efficacy. The experimental results are shown in Table 6 below.

In addition, paraffin sections were prepared by fixing the tissue, stained, observed under a microscope, and photographed. The photograph is shown in FIG. 4.

[Table 6] Treatment Effect of Acetic Acid-Induced Chronic Gastritis

According to the results of Table 6, it can be seen that the herbal extract of Example 4 has an excellent therapeutic effect on the subtype of gastric mucosal damage caused by acetic acid. In addition, from the photograph of FIG. 4, gastric wall (B) damaged by acetic acid compared to normal group (A) was treated by administering the herbal extracts (E, F) and Comparative Example 1 (C, D) of Example 4. It can be confirmed that the herbal extract of Example 4 has a concentration-dependent gastric damage inhibitory effect.

Formulation Example 1 Preparation of Tablet

Tablets for oral administration using the herbal extract prepared in Example 4 were prepared by granulation using wet granulation and dry granulation with the following composition, followed by tableting to prepare tablets.

Formulation Example 2: Preparation of Capsule

Using the herbal extract prepared in Example 4 to fill a gelatin capsule with the following composition to prepare a capsule.

Formulation Example 3: Preparation of Ointment

Using the herbal extract prepared in Example 4 to prepare an ointment with the following composition.

Formulation Example 4 Preparation of Injection

Using the herbal extract prepared in Example 4 to prepare an injection with the following composition.

Formulation Example 5 Preparation of Liquid

Using the herbal extract prepared in Example 4 to prepare a liquid formulation with the following composition.

Formulation Example 6 Preparation of Powder

Using the herbal extract prepared in Example 4 was mixed in the following composition and filled in an airtight fabric to prepare a powder.

Formulation Example 7: Preparation of Pills

Heat 100 mL of honey, filter it, heat it again, and filter again three or four times, then rub it with your hands to heat it until it becomes viscous, yellow dust, and not sticky in your hands after cooling. . Water, walnut oil and vinegar may be used instead of honey. The hot honey prepared as described above is kneaded by adding 5 g of the herbal extract prepared in Example 4, and then the dough is molded into a ring of equal size by using an artificial or a machine to prepare a pill. The prepared pills are dried in a cool and dry place and then stored in a cool and airtight place.

Formulation Example 8 Preparation of Suspending Agent

0.1 g of the herbal extract prepared in Example 4 was stirred and mixed in 100 mL of water with polyethylene glycol, polyvinylpyrrolidone, carboxymethylcellulose, bentonite, or polysorbate 80 as a suspending agent, sodium saccharin as a sweetener, A suspending agent is prepared according to a conventional method for preparing a suspending agent by mixing syrup, sugar, honey, or D-mannitol.

 Formulation Example 9 Preparation of Transdermal Agent

Using the herbal extract prepared in Example 4 to prepare a transdermal drug in the following manner.

Formulation Example 10 Preparation of Chewing Gum

Chewing gum is prepared using a conventional method using the herbal extract prepared in Example 4 in the following composition and content.

Formulation Example 11 Preparation of Beverage

Using the herbal extract prepared in Example 4 to prepare a beverage using conventional methods in the following composition and content.

Formulation Example 12 Preparation of Candy

Using the herbal extract prepared in Example 4 to prepare a candy using a conventional method with the following composition and content.

A mixture of 20% herbal extract and 80% crystalline lactitol is diluted with purified water and placed in a sauce pen. The batch is first heated on a hot plate until all material is solubilized, then the batch is transferred to a vacuum cooker and further heated. The formed blend forms a viscous mass even at relatively low temperatures. The syrup is then transferred from the cooker to the thick plate and cured until a suitable tissue is formed for drop rolling. The cured mass is fed through a drop roller. Once imprinted, the candy has an acceptable quality.

Formulation Example 13 Preparation of Alcohol (Alcohol)

Wash 650g of shiho, 150g of yellow lotus and 150g of licorice, put it in an extraction container, add 10,000mL of water, and decoctify for 3 hours at 100 ℃ to obtain an extract. Separately, after mixing evenly the Central America, traditional yeast 1kg and 5kg of juju made with 4kg of rice, pour the extract and fermented for about 3 days at 10 ~ 25 ㅀ C. The fermentation broth is filtered to separate the liquid and solid parts, heated to 55 ~ 60 ㅀ C, and then purified water is added to the filtrate to adjust to 10,000mL to prepare the main ingredient.

Claims (9)

1. A composition for preventing or treating gastrointestinal diseases, comprising two or more herbal drugs selected from the group consisting of Bupleuri Radix, Cooptidis Rhizoma, and Glycyrrhizae Radix.
2. The composition according to claim 1, comprising 10-30 parts by weight of rhubarb and 10-30 parts by weight of licorice with respect to 100 parts by weight of the seahawk.
3. The method according to claim 1, wherein the shiho, rhubarb, and licorice are each a crude extract itself, a dry extract of the crude drug, or a crude extract of a solvent selected from the group consisting of water, C ₁ -C ₄ alcohols, and combinations thereof. A composition, characterized in that.
4. The composition of claim 1, wherein the gastrointestinal disease is mucosal damage of the stomach or duodenum caused by alcohol, smoking, stress, drugs, or a combination thereof.
5. The composition of claim 1, wherein the gastrointestinal disease is gastritis, gastric ulcer, duodenal ulcer, Solinger-Elison syndrome, reflux esophagitis, postoperative ulcer, or erosion, bleeding, redness, or edema of the gastric mucosa.
6. A pharmaceutical product comprising the composition according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier or additive.
7. The pharmaceutical product according to claim 6, which is in the form of powder, granule, tablet, capsule, suspension, emulsion, syrup, liquid, aerosol, extract, injection, transdermal or suppository.
8. A health functional food comprising the composition according to any one of claims 1 to 5 and a food acceptable carrier or additive.
9. The health functional food according to claim 8, which is in the form of a liquid, suspension, powder, granule, tablet, capsule, pill, extract, tea, jelly, or beverage.

Images